智通财经APP讯，昭衍新药(603127.SH)发布公告，预计2024年实现营业收入约人民币191,741.71万元到人民币211,925.05万元，与上年同期的数据相比，将减少约人民币25,723.63万元到人民币45,906.97万元，同比下降约10.8%到19.3%。
预计2024年实现归属于上市公司股东的净利润约人民币5,868.80万元到人民币8,803.20万元，与上年同期的数据相比，将减少约人民币30,896.06万元到人民币33,830.46万元，同比下降约77.8%到85.2%。
预计2024年实现归属于上市公司股东的扣除非经常性损益的净利润约人民币1,789.20万元到人民币2,683.80万元，与上年同期的数据相比，将减少约人民币31,072.67万元到人民币31,967.27万元，同比下降约92.0%到94.7%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.